// App-Quantinova.ai

: Clinical experience with idebenone in the treatment of patients harboring rare mutations related to Leber's hereditary optic neuropathy (LHON)

Researchers

Presenter

  • X. Llria

Principal Investigators

  • C. Catarino

  • S. Downes

  • A. Vincent

  • S. Matloob

  • M. Silva

  • T. Klopstock

Medical Centers

  • Medical Affairs, Santhera Pharmaceuticals, Liestal, Switzerland

  • Department of Neurology, Friedrich‐Baur‐Institute, Munich, Germany

  • Clinical Neurosciences, University of Oxford, Oxford, United Kingdom,

  • Ophthalmology, University of Auckland, Auckland, New Zealand

  • Ophthalmology, Waikato Hospital, Hamilton, New Zealand

Locations

  • Switzerland

  • Germany

  • United Kingdom

  • New Zealand

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Ophthalmology (OP)

Disease

  • Optic neuropathy

  • Leber optic atrophy

Biomarkers

  • Twist-related protein 1

Drug/Treatment

  • Idebenone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved